U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 ... ...

Seasoned leader with global commercialization and marketing expertiseSOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company’s global ...

Core Insights - Amgen is optimistic about 2026, viewing it as a pivotal year with significant clinical data expected to be generated [2] Group 1: Company Overview - Amgen operates in four general therapeutic areas, focusing on diseases with high unmet medical needs [3] - The company offers first-in-class and best-in-class innovative medicines, including branded biosimilars [4] Group 2: Financial Performance - Over the past decade, Amgen has achieved consistent revenue and earnings growth, reflecting the success of its product offerings [4]

Summary of Amgen's Conference Call Company Overview - **Company**: Amgen - **Industry**: Biotechnology and Pharmaceuticals - **Key Focus Areas**: Therapeutics for unmet medical needs, including cardiovascular diseases, osteoporosis, severe asthma, and rare diseases [2][3] Financial Performance - **2025 Revenue Growth**: 10% increase in revenues, driven by 14 blockbuster products [4] - **Earnings Growth**: 14% increase in earnings per share [4] - **Debt Reduction**: Over $6 billion in debt paid down in 2025 [6] Key Products and Growth Drivers - **Repatha**: - Annualized sales of approximately $3 billion, growing at 33% [7] - Demonstrated a 36% reduction in heart attack risk in primary prevention [5] - Significant market opportunity with over 100 million people at risk of heart attacks [9] - **Evenity**: - Sales growth of over 30%, targeting women at high risk of osteoporotic fractures [10] - Urgent need for treatment due to high mortality rates post-fracture [47] - **Tezspire**: - Innovative treatment for severe asthma and chronic rhinosinusitis with nasal polyps [10] - Strong clinical performance and potential for expansion into COPD and eosinophilic esophagitis [10] - **Biosimilars**: - 42% year-over-year sales growth, contributing $13 billion since entry into the market [15] - **Rare Disease Portfolio**: - Approached $5 billion in sales, with ongoing expansion into new indications [11] Pipeline and Future Prospects - **MariTide**: - Focused on obesity and type 2 diabetes, with six phase 3 studies initiated [19] - Potential for monthly or less frequent dosing, addressing treatment persistence issues [20][21] - **Olpazeran**: - Targets Lp(a) reduction, a significant risk factor for cardiovascular disease, with potential for 95%-100% reduction [38] - Expected to provide a long-acting treatment option for patients [39] - **Imdeltra**: - Bispecific T-cell engager for small cell lung cancer, showing promise in early lines of therapy [13] Market Dynamics and Strategic Focus - **Obesity Market**: - Anticipated growth due to increasing recognition of obesity as a chronic disease [29] - Amgen aims to position itself as a key player in this evolving landscape [30] - **Capital Allocation**: - Focus on investing in innovation and manufacturing capabilities to maintain competitive advantage [25] - **Technological Integration**: - Emphasis on incorporating technology and AI to enhance operational efficiency [24] Conclusion - Amgen is positioned for significant growth in 2026 and beyond, driven by a robust pipeline of innovative therapies and a strong financial foundation. The company is focused on addressing high unmet medical needs across various therapeutic areas, with a commitment to maintaining operational discipline and investing in future growth opportunities [27]

Core Insights - Amgen's experimental obesity drug MariTide has shown effectiveness in helping individuals maintain weight loss in an extension study [1] - A second mid-stage trial indicated that MariTide also reduced blood sugar levels in diabetes patients [1] Summary by Category Drug Efficacy - MariTide assists in weight maintenance post-weight loss, demonstrating its potential as a long-term treatment option for obesity [1] - The drug has shown promising results in lowering blood sugar levels among patients with diabetes, indicating its dual therapeutic potential [1]

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if the medication helps people maintain weight loss. ...

44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Provided January 12, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 2 We Have a Broad and Deep Portfolio Across Four Therapeutic Areas ROBERT A. BRADWAY, Chairman and Chief Executive Officer January 12, 2026 Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs o ...

“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2 SKYWAY basket trial enrollment on track across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA); All readouts expected in 4Q 2026 Kate Tansey Chevlen appointed Chief Commercial Officer (CCO) Stro ...

Market Overview - The Dow Jones Industrial Average increased by 270.03 points (0.55%) to reach 49266.11, while Dow Futures rose by 144.00 points (0.29%) to 49637.00, indicating positive movement in the blue-chip index amidst a mixed broader market [1] - The S&P 500 remained essentially flat, and the Nasdaq Composite lagged due to declines in tech stocks [1] Economic Data Impact - The primary narrative driving the market was the release of US employment data, which showed fewer jobs added than expected but a lower unemployment rate [2] - Anticipation of a possible Supreme Court ruling on President Trump's tariffs contributed to market uncertainty [2] Sector Rotation - There was a notable rotation from high-flying tech stocks, particularly in the AI sector, into more defensive and value-oriented segments such as industrials and financials, driven by profit-taking and concerns over elevated valuations [2] Company Performance - Among the Dow's constituents, Home Depot (HD) led the gainers with a surge of 3.85%, followed by Nike (NKE) with a 3.02% increase, and Chevron (CVX) up 2.98% due to shifts in the oil market [3] - Other strong performers included Sherwin-Williams (SHW) (+2.90%) and Honeywell (HON) (+2.87%) [3] - Conversely, Amgen (AMGN) was the biggest decliner, falling by 3.26%, with Nvidia (NVDA) down 2.16% and Salesforce (CRM) down 2.06%, reflecting a broader pullback in technology and AI-related shares [3]

Core Insights - Exelixis, Inc. is a biotechnology company focused on developing cancer treatments, particularly known for its innovative therapy cabozantinib [1] - The company is competing with other biotech firms like Amgen and Gilead Sciences in the oncology sector [1] Stock Performance and Analyst Outlook - Robert Burns from H.C. Wainwright set a price target of $52 for Exelixis, indicating a potential upside of 16.1% from the current trading price of $44.79 [2] - Following the announcement of the collaboration with Natera, Exelixis' stock increased by 6% on January 7, reflecting positive market sentiment [4] - Over the past year, Exelixis' shares have risen by 33.9%, significantly outperforming the industry gain of 17.2% [4][6] Collaboration and Clinical Trials - Exelixis announced a collaboration with Natera for the phase III STELLAR-316 study, focusing on the efficacy of zanzalintinib in patients with resected stage II/III colorectal cancer [3][6] - The trial will evaluate zanzalintinib both with and without an immune checkpoint inhibitor, with the primary endpoint being disease-free survival, expected to start in mid-2026 [3] Current Market Data - Exelixis' current stock price is approximately $44.74, showing a decrease of about 3.14% or $1.45 [5] - The stock has fluctuated between a low of $44.39 and a high of $45.84 during the trading day [5] - The company has a market capitalization of approximately $11.99 billion, with a trading volume of 561,415 shares [5]